JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265037

Human SLC7A6 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

SLC7A6 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 4 and Insertion of the selection cassette in exon 4.

View Alternative Names

AI643885, Cationic amino acid transporter y+ system, DKFZp686K15246, KIAA0245, Solute carrier family 7 (cationic amino acid transporter y+ system) member 6, Solute carrier family 7 member 6, Y+L amino acid transporter 2, y(+)L type amino acid transporter 2, y+LAT 2

2 Images
Sanger Sequencing - Human SLC7A6 knockout HeLa cell line (AB265037)
  • Sanger seq

Unknown

Sanger Sequencing - Human SLC7A6 knockout HeLa cell line (AB265037)

Allele-1 : 1 bp deletion in exon 4.

Sanger Sequencing - Human SLC7A6 knockout HeLa cell line (AB265037)
  • Sanger seq

Unknown

Sanger Sequencing - Human SLC7A6 knockout HeLa cell line (AB265037)

Allele-2 : Insertion of the selection cassette in exon 4.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 4 and Insertion of the selection cassette in exon 4

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255448). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265037-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265037 Human SLC7A6 knockout HeLa cell line", "number":"AB265037-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265037-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265037 Human SLC7A6 knockout HeLa cell line", "number":"AB265037-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
SLC7A6
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

SLC7A6 also known as LAT-2 is a protein that functions as part of the heterodimeric amino acid transporter complex. It has a molecular mass of approximately 55 kDa. This protein is primarily expressed in the liver and kidney but it can also be found in other tissues such as the skeletal muscles and brain. SLC7A6 is involved in the transportation of neutral and cationic amino acids across cell membranes which is essential for maintaining cellular homeostasis.
Biological function summary

The SLC7A6 protein participates in amino acid transport across the plasma membrane and it forms a functional complex with the glycoprotein 4F2hc/CD98. This association is necessary for the optimal activity and localization of SLC7A6 on the cell surface. Its role in amino acid exchange impacts nutrient sensing and plays a critical function in cellular growth and repair processes. The protein is involved in maintaining amino acid balance which is fundamental in many physiological processes.

Pathways

Amino acid transporters like SLC7A6 are significant in metabolic and mTOR signaling pathways. These pathways influence cellular growth proliferation and metabolism. SLC7A6 is closely related to other transporters like SLC7A5 within these pathways catalyzing the bidirectional movement of large neutral amino acids. It ensures the availability of essential amino acids for protein synthesis and energy production affecting the overall metabolic state of the cell.

Altered expression of SLC7A6 is linked to metabolic disorders and cancer. Disruption in its function can lead to amino acid imbalances contributing to the development of liver diseases. Additionally cancer cells often show increased expression of amino acid transporters like SLC7A6 and SLC7A5 to fulfill the high nutrient demands of rapidly dividing cells indicating its importance in cancer metabolism and potential as a therapeutic target.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com